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Abstract
Background: Use of artemisinin-based combination therapy (ACT), such as artemether-lumefantrine (AL), requires a
strict dosing schedule that follows the drugs’ pharmacokinetic properties. The quality of malaria case management
was assessed in two areas in rural Tanzania, to ascertain patient characteristics and facility-specific factors that
influence correct dosing of AL for management of uncomplicated malaria.
Methods: Exit interviews were conducted with patients attending health facilities for initial illness consultation.
Information about health workers’ training and supervision visits was collected. Health facilities were inventoried for
capacity and availability of medical products related to care of malaria patients. The outcome was correct dosing of
AL based on age and weight. Logistic regression was used to assess health facility factors and patient characteristics
associated with correct dosing of AL by age and weight.
Results: A total of 1,531 patients were interviewed, but 60 pregnant women were excluded from the analysis. Only
503 (34.2%) patients who received AL were assessed for correct dosing. Most patients who received AL (85.3%)
were seen in public health facilities, 75.7% in a dispensary and 91.1% in a facility that had AL in stock on the survey
day. Overall, 92.1% (463) of AL prescriptions were correct by age or weight; but 85.7% of patients received correct
dosing by weight alone and 78.5% received correct dosing by age alone. In multivariate analysis, patients in the
middle dosing bands in terms of age or weight, had statistically significant lower odds of correct AL dosing
(p < 0.05) compared to those in the lowest age or weight group. Other factors such as health worker supervision
and training on ACT did not improve the odds of correct AL dosing.
Conclusion: Although malaria treatment guidelines indicate AL dosing can be prescribed based on age or weight
of the patient, findings from this study show that patients within the middle age and weight dosing bands were
least likely to receive a correct dose by either measure. Clinicians should be made aware of AL dosing errors for
patients aged three to 12 years and advised to use weight-based prescriptions whenever possible.
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Background
The World Health Organization (WHO) declared that
much of ill health, disease, premature death, and suffering
are needless, since efficacious and affordable interventions
for prevention and treatment are available. It is further
noted that these effective interventions are not matched
by the strength of health systems to deliver them to those
in greatest need in a comprehensive way and on an
adequate scale [1]. This fact highlights the need to assess
and address health systems’ bottlenecks, in order to im-
prove health outcomes and the quality of health care
services.
Following widespread resistance by malaria parasites
to commonly used anti-malarials, such as chloroquine and
sulphadoxine-pyrimethamine (SP), there was a global
move to use artemisinin-based combination therapy
(ACT) for malaria treatment [2]. This required the arte-
misinin derivatives with shorter half-life be combined with
a longer half-life partner drug, to enhance therapeutic
efficacy and reduce treatment durations [2]. Currently, the
artemisinin derivatives used for malaria combination
treatment include artesunate, artemether, and dihydroar-
temisinin (DHA). ACT, such as artemether-lumefantrine
(AL), became first-line medicine for management of un-
complicated malaria in many malaria-endemic countries,
including Tanzania [3].
Good quality malaria case management entails that all
true malaria cases be appropriately identified, and that all
identified cases be treated with efficacious anti-malarial
medicines. To achieve desired treatment outcomes, suffi-
cient blood levels of the active medical ingredient must be
reached. The increased use of microscopy and malaria
rapid tests for parasitological confirmation of malaria im-
proves identification of true malaria patients. Despite the
limitations of malaria rapid tests, these tests have been
introduced in routine care and have resulted in better tar-
geting of anti-malarials in endemic countries [4,5]. Pre-
vious studies in malaria endemic countries in Sub-Saharan
Africa have documented factors affecting quality malaria
case management. Challenges related to under-use of
malaria testing, distrust of negative results, ambiguous
treatment policies and un-availability of recommended
medicines are contributing factors [6,7].
Poor adherence and inappropriate use of recommended
treatment have been linked to the development and
spread of drug resistance [8,9]. Use of medicines requires
a strict dosing schedule that aligns with the drug’s
pharmacokinetics [10]. The current dosing of AL is based
on four predefined weight bands and age groups. Accor-
ding to manufacturers, an eight-hour interval between the
first and the second doses of AL is critical for appropriate
parasite clearance and clinical cure. In addition, manu-
facturers recommend completing the doses at defined
time intervals and taking AL with a fatty meal for better
absorption of the drug to enhance its bioavailability.
These recommendations, if followed thoroughly, will
optimize therapeutic response. Unfortunately many
studies have reported that clinical practice differs for
various reasons [7,11,12].
Packaging of AL medicines for public sector use in
Tanzania is customized for each dosing band and incor-
porates illustrated instructions for patients and care-
takers with low literacy. Both age-based or weight-based
AL dosing recommendations are included in the guide-
lines [3], and therefore it is at service provider’s dis-
cretion to prescribe based on either of the two dosing
methods. This study was carried out to assess the quality
of malaria case management, including an assessment of
AL dosing, in a real world setting. Factors influencing
correct AL dosing were explored to inform disease con-
trol programme and local health management teams
to plan effective malaria-related supportive supervision,
focusing on areas that require emphasis.
Methods
Study design and study area
Data were collected through a pair of cross-sectional
health facility surveys in the Rufiji and Ifakara Health
and Demographic Surveillance System (HDSS) areas, in
March and October 2010. All health facilities, public and
private, within the HDSS areas were included in the sur-
vey; 16 health facilities from Rufiji HDSS and 14 health
facilities from Ifakara HDSS, as previously described [5].
This work was completed as part of the large phase 4
platform of the INDEPTH Network to assess effec-
tiveness and safety of anti-malarial drugs called INESS-
Indepth Network Effectiveness and Safety Studies of
anti-malarial drugs [13].
Data collection
All outpatients presenting for initial illness consultation
on the day of a survey were approached to assess eligibility
and seek consent for inclusion in the study. Information
was collected by means of paper questionnaires and
through interviews with patients or caretakers. Informa-
tion on patients’ complaints, provider’s diagnosis, dosing
instructions, and counselling messages were recorded.
Patients’ clinical notes were later reviewed for similar in-
formation to ascertain concordance between patients’ nar-
ration and clinical notes. Information from clinical notes
was also recorded in the questionnaire. Patients were
weighed and asked for a blood smear for independent
assessment of presence of malaria parasites. Results of
microscopic analysis of blood smears were not available
immediately for clinical judgement; but were sent back to
the facility after two or three days. Information on pro-
vider’s training, work experience and supervision visits
were also recorded. The facilities were inventoried for
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availability of medicines, diagnostics, and reference mate-
rials related to malaria treatment.
Data entry and analysis
Data were entered in EPIDATA Entry version 3.1 (EpiData
Association, Odense, Denmark) by two independent entry
clerks. Analysis was performed in STATA 11 (StataCorp,
College Station, Texas, USA). Descriptive analysis was
undertaken after merging health facility, health worker
and patient datasets. Pearson Chi-squared test was used to
compare proportions of patients who received correct AL
dose based on age and/or weight by different patients’
characteristics and facility factors. Logistic regression was
carried out to assess association of health facility factors
and patients’ characteristics with correct AL dosing.
Health facility factors assessed were type of facility, super-
vision within the past six months, training on AL, avai-
lability of reference materials on treatment guideline as
well as presence of AL, diagnostics, and weighing scales.
Patients’ characteristics assessed were age, weight, fever or
history of fever in the previous 24 hours, laboratory tests
performed, and treatment provided. All predictors of
correct dosing were run simultaneously in the adjusted
model. An alpha level of 0.05 was used for all significance
tests. All analyses accounted for the complex sample
survey design of this study and accounted for clustering
with the cluster defined as all consultations conducted in
a health facility in one day.
Definition of correct dosing of artemether-lumefantrine
A composite measure was developed to assess correct
dosing of AL based on two criteria: i) appropriate number
of AL tablets per dose given based on patient’s age or body
weight as per national malaria treatment guideline [3],
and, ii) appropriate number of doses, i.e., two doses per
day for three days. Any dosing instruction that did not
meet these criteria was considered inappropriate.
Ethical clearance
This work was granted ethical permit from the Ifakara
Health Institute (IHI/IRB/No. A 67–2009) and the National
Institute for Medical Research in Tanzania (NIMR/HQ/
R.8a/Vol.IX/871).
Results
Of the 1,531 patients who were interviewed, only 503
(32.8%) who received AL were included in the analysis
(Figure 1). Table 1 shows the baseline characteristics of
patients included in the larger study of case manage-
ment quality in the HDSS areas. The majority of patients
included in the dosing analysis were seen in dispensaries
381 (75.7%) and public health facilities 429 (85.3%)
Total patients seen in Health 
Facilities = 
Total patients included in the general 
analysis = 
Pregnant 
women 
excluded = 
Patients with clinical malaria and/ 
or other diagnoses = 681 (46.3%)
Patients with uncomplicated malaria at 
health facility = 790 (53.7%)
Patients who received AL at 
health facility= 433 (433/790: 
Patients who received AL at 
health facility = 70 
All AL prescription at health facility; 
included for assessment of correct dosing of AL 
1531 
1471 (100%)
60
Figure 1 Distribution of study participants.
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(Table 2). Most patients who were prescribed with AL
were seen in a facility that had AL in stock on the day of
a survey 458 (91.1%), but only 55.3% (278) patients were
seen in a facility with malaria diagnostic test available on
the survey day. Although 367 (72.9%) patients were seen
in a facility that had a functioning weighing scale, only a
third 170 (33.8%) had their weight measured and re-
corded during a provider-patient interaction, but almost
all patients 482 (95.8%) had their age assessed and re-
corded during clinical consultation. Very few patients
were seen by a health worker who had had a supervision
visit in the previous six months 110 (21.8%) or who had
training on AL use 224 (44.5%). Most patients reported
fever or history of fever in the previous 24 hours 488
(97.2%) but only about half of them 223 (44.3%) were
sent for malaria testing at the facility.
In all, (463) 92.1% of patients who were prescribed AL
received correct dosing by weight and/or age, as indi-
cated in national treatment guidelines (Table 3), and
(431) 85.7% of patients received correct dosing based on
weight alone and (395) 78.5% based on age alone. As-
sessment of patients’ characteristics (age and weight)
indicated that the proportion of patients who received
correct AL dosing was significantly lower in patients
within the middle weight bands, i.e., between 15 and
25 kg and 25 and 35 kg, and middle age bands, three to
nine years and nine to 12 years (p < 0.001).
In a multivariate analysis, the most important factor
for incorrect dosing was patients aged between three
and 12 years and body weight >15 to 35 kg compared to
children below age three years and <15 kg, respectively
(Table 4). Private providers (non-public facilities) also
had lower odds of correct dosing in the adjusted analysis
(adjusted odds ratio (aOR) 95% confidence interval (CI)):
0.2 (0.06-0.6)). Other factors such as availability of refer-
ence materials, supervision, training, availability of AL,
and weighing scales at facility were not associated with
correct AL dosing (Table 3).
Table 5 describes the relationship between patients’
age and weight based on AL dosing criteria. The findings
indicate that the weight for age are not concordant for
the two middle weight groups (15-25 kg and >25-35 kg).
There are patients who weigh less or more than ex-
pected compared to their age group. For example, a total
of 144 patient aged three to nine years were expected to
receive two AL tablets corresponding to weight band
15- < 25 kg, but only 73 (50.7%) fell in this weight band;
67 (46.5%) had low weight for age and four (2.8%)
weighed too much for their age.
Discussion
This study assessed the association of health facility and
patient characteristics to correct AL dosing for the treat-
ment of uncomplicated malaria in rural Tanzania. Malaria
treatment guidelines in Tanzania follow manufacturers’
recommendations, which allow for both age- and weight-
based AL dosing [3]. More than four years after the intro-
duction of AL, correct AL dosing was suboptimal in some
patient groups, especially children aged three to 12 years.
Other health facility and patient factors were not asso-
ciated with correct dosing.
Concerns about incorrect dosing of anti-malarial drugs
have been reported in other settings [6,7,14]. In particular,
a study from Kenya showed that infants were more likely
to receive appropriate treatment than older children [11];
the authors suggested that health workers were being
more careful with the younger age group, which seems a
logical explanation for the observation. In this study,
35.2% of all patients receiving AL were children aged three
to 12 years, many of whom did not receive correct AL
dosing. Correct AL dosing is particularly important for
children as they are more likely to contract malaria, more
likely to progress to severe illness, and more likely to die
from malaria than adults.
Although, 92.1% of patients received correct AL dosing
by age or weight criteria, fewer received correct dosing by
Table 1 Baseline characteristics of all patients included in
the survey, by HDSS site
Facility/patients
characteristic
All sites:
N = 1471(%)
Rufiji:
n = 710 (%)
K/U:
n = 761 (%)
Type of health facility:
Seen in dispensaries 1037 (70.5) 477 (67.2) 560 (73.6)
Seen in health centers 403 (27.4) 202 (28.5) 201 (26.4)
Seen in hospitals 31 (2.1) 31 (4.4) 0
Health facility ownership:
Seen in Public HFs 1179 (80.0) 543 76.5) 636 (83.6)
Seen in Non-public HFs 292 (20.0) 167 (23.5) 125 (16.4)
Availability:
Seen in HF with functioning
scale for all age
1428 (97.0) 697 (98.2) 731 (96.1)
Seen in HF with malaria
diagnostic capacity
881 (60.0) 527 (74.2) 354 (46.5)
Seen in HF AL in stock 1268 (86.2) 666 (93.8) 602 (79.1)
Seen in HF with treatment
reference materials
1293 (87.9) 604 (85.1) 689 (94.4)
Health worker (HW) factors:
Seen by HW trained on
AL use
837 (57.0) 219 (30.9) 618 (81.2)
Seen by HW supervised in
past 6 months
1004 (68.3) 474 (66.8) 530 (75.6)
Patients characteristics:
Age <5 years 701 (47.7) 349 (49.2) 352 (46.3)
Age 5–15 years 246 (16.7) 112 (15.8) 134 (18.0)
Age >15 years 524 (35.6) 249 (35.1) 275 (36.0)
Fever or history of fever 1247 (84.8) 620 (87.3) 627 (82.4)
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weight-based criteria alone (85.7%) or age-based criteria
alone (78.5%). Our analysis of weight versus age profile of
this patient population suggests that the weight-to-age
profile needs to be adapted to the local population
context. Although, the weight-to-age profile matches for
children <3 kg (98.8% concordant with age) and per-
sons >35 kg (95.3% concordant with age), the weight-
to-age profile does not match for children 15 to <25 kg
(50.7% concordant) and for children 25 to <35 kg (42.4%
concordant); most of the dosing errors based on age alone
would lead to overdosing compared to dosing based on
weight alone. In addition, weight-based prescriptions
should be better implemented to ensure appropriate
dosing. In this study, almost all (95.8%) of patients had
their age assessed, but only 33.8% of patients had their
weight assessed. Thus, to improve weight-based dosing
health workers should be encouraged to assess weight in
all patients.
AL is supplied to health facilities in four different dose
packs. An informal observation during the survey found
that in the event that a correct AL dose pack for the ap-
propriate age or weight group was not in stock, the pro-
vider would use any AL package to compensate for the
missing package. For example, an 11 year old who needs
three AL tablets dose (pink package), may receive two
packs: one blue pack (toddler package with two AL
Table 2 Distribution of patients who received
artemether-lumefantrine by health facility, health
worker and patient characteristics (N = 503)
Patient seen in (type of) health facility: n (%)
Dispensary 381 (75.7)
Health centre 114 (22.7)
Hospital 8 (1.6)
Public health facility 429 (85.3)
Non-public health facility 74 (14.7)
Availability at health facility:
Artemether-lumefantrine in stock 458 (91.1)
Diagnostic capacity rapid diagnostic test or
functional microscopy available
278 (55.3)
Weighing scale available 367 (72.9)
Printed copy of malaria treatment guidelines or
reference available
411 (81.7)
Patient seen by health worker who had:
Supervision in previous six months 110 (21.8)
Training on use of artemether-lumefantrine 224 (44.5)
Patient age groups:
Aged <3 years 177 (35.2)
Aged 3 to <9 years 144 (28.6)
Aged 9 to <12 years 33 (6.6)
Aged 12 years and above 149 (29.6)
Patient weight groups:
Weight <15 kg 245 (48.7)
Weight 15 to <25 kg 89 (17.7)
Weight 25 to <35 kg 24 (4.8)
Weight 35 kg and above 145 (28.8)
Other characteristics:
Presented with fever/history of fever in
previous 48 hours
488 (97.0)
Had weight assessed/recorded 170 (33.8)
Had age assessed/recorded 482 (95.8)
Had fever and a malaria test performed
at health facility
223 (44.3)
Table 3 Proportion of patients who received correct
dosing of artemether-lumefantrine based on age and/or
weight, by health facility, health worker and patient
characteristics
Patient seen in health facility n (%) p- value
Dispensary (N = 381) 350 (91.8) 0.827
Health centre (N = 114) 106 (93.0)
Hospital (N = 8) 7 (87. 5)
Public health facility (N = 429) 398 (92.7) 0.147
Non-public health facility (N = 74) 65 (87.8)
Availability at health facility:
Artemether-lumefantrine in stock (N = 458) 422 (92.1) 0.808
Diagnostic capacity (mRDT or
functional BS:N = 278)
256 (92.1) 0.972
Weighing scale available (N = 367) 340 (92.6) 0.418
Copy of malaria treatment guidelines
or reference (N = 411)
379 (92.2) 0.771
Patient seen by health worker who had:
Supervision in previous six months (N = 110) 100 (90.9) 0.618
Training on use of artemether-lumefantrine
(N = 224)
203 (90.6) 0.291
Patient age:
Aged <3 years (N = 177) 172 (97.2) <0.001
Aged 3 to <9 years (N = 145) 123 (84.8)
Aged 9 to <12 years (N = 33) 27 (81.8)
Aged 12 years and above (N = 148) 141 (95.3)
Patient weight:
5 -15 kg (N = 241) 234 (97.1) <0.001
>15 -25 kg (N = 88) 70 (79.5)
>25- 35 kg (N = 24) 18 (75.0)
>35 kg (N = 150) 141 (94.0)
Other characteristics:
Had fever with present illness (N = 488) 449 (92.0) 0.852
Correct dosing by age or/and weight (N = 503) 463 (92.1)
Correct dosing by weight only (N = 503) 431 (85.7)
Correct dosing by age only (N = 503) 395 (78.5)
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Table 4 Predictors of correct dosing of artemether-lumefantrine by age and/or weight
Patient seen in health facility (N) n (%) Crude OR (95% CI) Adjusted OR (95% CI)
Dispensary (N = 381) 350 (91.8) 1.6 (0.1-19.6) 2.5 (0.2-26)
Health centre (N = 114) 106 (93.0) 1.8 (0.1-16.3) 1.7 (0.2-17)
Hospital (N = 8) 7 (87.5) Ref Ref
Public health facility (N = 429) 398 (92.8) Ref Ref
Non-public health facility (N = 74) 65 (87.8) 0.5 (0.2-1.2) 0.2 (0.06-0.6)
Availability at health facility:
Artemether-lumefantrine in stock (N = 458) 422 (92.1) 1.1 (0.4-2.9) 0.9 (0.4-2.1)
No artemether-lumefantrine in stock (N = 45) 41 (91.1) Ref Ref
Diagnostic capacity: mRDT or functional BS (N = 278) 256 (92.1) 1.0 (0.5-2.0) 1.8 (0.5-6.1)
No diagnostic capacity (N = 225) 207 (92.0) Ref Ref
Weighing scale available (N = 367) 340 (92.6) 0.7 (0.3-1.5) 0.6 (0.3-1.5)
No weighing scale available (N = 136) 123 (90.4) Ref Ref
Copy of treatment guidelines or reference (N = 411) 379 (92.2) 1.1 (0.5-2.6) 0.6 (0.2-1.4)
No copy of guideline (N = 92) 84 (91.3) Ref Ref
Patient seen by health worker who had:
Supervision in previous six months(N = 110) 100 (91.0) 0.8 (0.3-1.9) 0.6(0.3-1.0)
No supervision previous six months (N = 393) 363 (92.4) Ref Ref
Training on use of artemether-lumefantrine (N = 224) 203 (90.6) 0.7 (0.4-1.3) 0.5 (0.2-1.2)
No training on use of artemether-lumefantrine (N = 279) 260 (93.2) Ref Ref
Patient age:
<3 years (N = 177) 172 (97.2) Ref Ref*
3- <9 years (N = 145) 123 (84.8) 0.1 (0.05-0.5) 0.1 (0.04-0.4)
9- <12 years (N = 33) 27 (81.8) 0.1(0.04-0.4) 0.1 (0.03-0.3)
12 years and above (N = 148) 141 (95.3) 0.6 (0.2-1.9) 0.6 (0.2-2.2)
Patient weight:
5 -15 kg (N = 241) 234 (97.1) Ref Ref*
>15 -25 kg (N = 88) 70 (79.5) 0.1 (0.04-0.3) 0.1 (0.03-0.3)
>25- 35 kg (N = 24) 18 (75.0) 0.1 (0.03-0.2) 0.06 (0.01-0.2)
>35 kg (N = 150) 141 (94.0) 0.6 (0.2-2.1) 0.8 (0.2-2.8)
Other characteristics:
Had fever with present illness (N = 463) 449 (92.0) 1.2 (0.2-6.5) 0.6 (0.07-4.5)
No fever this illness (N = 15) 14 (93.2) Ref Ref
*Due to collinearity of age and weight, multivariate models did not include both age and weight in a single model.
Table 5 Relationship between weight and age of patients who received artemether-lumefantrine based on
recommended artemether-lumefantrine dosing bands (N = 503)
Dosing criteria Age <3 years 3 - <9 years 9 t - < 12 years 12 years and above Total
<15 kg 175 (98.8%) 67 (46.5%) 2 (6.1%) 1 (0.7%) 245 (48.7%)
15-25 kg 2 (0.2%) 73 (50.7%) 14 (42.4%) - 89 (17.7%)
>25-35 kg - 4 (2.8%) 14 (42.4%) 6 (4.0%) 24 (4.8%)
>35 kg - - 3 (9.1%) 142 (95.3%) 145 (28.8%)
Total 177 (100%) 144 (100%) 33 (100%) 149 (100%) 503 (100%)
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tablets per dose) and one yellow pack (baby package with
one tablet per dose). This strategy might not always work
well and might confuse the patient about the appropriate
number of pills required. More assessment of this phe-
nomenon is needed to understand its effect in providing
adequate care for malaria patients. In addition, we do not
know the impact of uniform AL packaging (e.g. adults
only, or loose tablets) on correct AL dosing.
During treatment policy change it is customary to train
health workers on new guidelines and provide reference
materials for use upon returning to the health facility. In
this assessment, neither health workers’ training on AL
use nor possession of reference material improved the
odds of correct AL dosing. One explanation for this fin-
ding could be that it takes time and experience for
trainees to be competent in new topics. This underscores
the need for frequent supervision from health manage-
ment teams, with possibilities of refresher training and/
or on-the-job training, to complement formal training.
Moreover, training content, modality, and duration
could influence providers’ understanding and perfor-
mance post-training; all of which were not assessed in
this study.
Receipt of supervisory visits was not associated with
correct dosing, and very few patients (21.8%) were seen by
providers who have had a supervisory visit in the previous
six months. The study did not assess the type or content
of supervision, which might be important factors. The role
of supervision visits in improving quality of malaria case
management has provided inconsistent conclusions in
other settings [11]. However, understanding predictors of
appropriate care for malaria patients can assist health
managers in planning resources and performing suppor-
tive supervision with emphasis on areas seem to be chal-
lenging, in order to improve the quality of services and
support disease control measures.
Limitations
No information was collected on total number of pa-
tients attended by a provider to assess caseload and how
it may have affected quality of care, but all patients and
providers on the day of survey were included, hence the
patient sample is self-weighting on the basis of
utilization for the days surveyed, assuming survey days
were typical for the rest of the year. The importance of
caseload assessment has been described elsewhere
[6,11,15].
Conclusions
Correct AL dosing in the study areas was generally high,
but children aged three to 12 years were significantly less
likely to receive correct AL dosing. Health workers
should be made aware of the possibility of incorrect do-
sing for older children and young adults in the middle
age and weight categories of the current AL formulation
in use. Supportive measures to ensure availability of
basic equipment and an emphasis on weight-based AL
dosing should be made to improve clinical practise.
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